clofibric acid has been researched along with Idiopathic Parkinson Disease in 2 studies
Clofibric Acid: An antilipemic agent that is the biologically active metabolite of CLOFIBRATE.
clofibric acid : A monocarboxylic acid that is isobutyric acid substituted at position 2 by a p-chlorophenoxy group. It is a metabolite of the drug clofibrate.
| Excerpt | Relevance | Reference |
|---|
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mutez, E | 1 |
| Duhamel, A | 1 |
| Defebvre, L | 1 |
| Bordet, R | 1 |
| Destée, A | 1 |
| Kreisler, A | 1 |
| Becker, C | 1 |
| Jick, SS | 1 |
| Meier, CR | 1 |
2 other studies available for clofibric acid and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Lipid-lowering drugs are associated with delayed onset and slower course of Parkinson's disease.
Topics: Clofibric Acid; Diabetes Complications; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase I | 2009 |
Use of statins and the risk of Parkinson's disease: a retrospective case-control study in the UK.
Topics: Aged; Aged, 80 and over; Body Mass Index; Case-Control Studies; Clofibric Acid; Comorbidity; Databas | 2008 |